Autopsy report · NCT02275481

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“lack of enrollment”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 10 months before it stopped.
66 participants enrolled.
Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status: Terminated
Phase: Phase 4
Sponsor: Sumitomo Pharma America, Inc.
Sponsor type: Industry
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Arformoterol tartrate inhalation solution; Tiotropium
Participants: 66
Sites: 28
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.